Business
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
Avidity Biosciences, Inc. ("Avidity") (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCs™") to profoundly improve people's lives, today announced that it intends to convene its upcoming special meeting of stockholders (the "Special Meeting") scheduled for February 23, 2026, at 10:00 a.m., Eastern time, and then immediately adjourn proceedings, without conducting any other business. Avidity intends t
About this update from Atrium Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCs™") to profoundly improve people's lives, today announced that it intends to convene its upcoming special meeting of stockholders (the "Special Meeting") scheduled for February 23, 2026, at 10:00 a.m., Eastern time, and then immediately adjourn proceedings, without conducting any other business. Avidity intends to reconvene the Special Meeting on February 26, 2026, at 10:00 a.m., Eastern time. Stockholders who have already registered for the Special Meeting will not need to re-register for the reconvened Special Meeting, which will be accessible via the same virtual meeting link: www.proxydocs.com/RNA.","length":870,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Avidity Biosciences, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Avidity Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":188,"url":"https://media.zenfs.com/en/prnewswire.com/d3ba411dafc5b9fe6b77b592275c9c79"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CUqGwDlJgRQuW4SSqvStJg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMzMTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d3ba411dafc5b9fe6b77b592275c9c79","width":400,"height":188}},"href":"https://mma.prnewswire.com/media/974628/Avidity_Biosciences_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Avidity intends to adjourn the Special Meeting to provide additional time to satisfy the conditions to the pro rata distribution of all of the issued and outstanding shares of Atrium Therapeutics, Inc. ("SpinCo") common stock to Avidity's stockholders (the "Distribution"). The Distribution is a condition to the closing of Avidity's previously announced proposed merger with Novartis AG (the "Merger").","length":441,"tagName":"p"},{"type":"text","content":"Avidity also announced that the Distribution is expected to occur on February 26, 2026 and the closing of the Merger is expected to occur on February 27, 2026. The completion of the Distribution and the Merger each remain subject to the respective closing conditions noted in Avidit...